**Suppl. Table 1.** Immunological assessment per group prior to MV130 vaccination

|                  | MGUS No: 7          | NHL No: 6         |
|------------------|---------------------|-------------------|
| IgG (mg/dL)      | 1,302±722           | 484±194           |
|                  | 1,062 (1590)        | 431 (274)         |
| IgA (mg/dL)      | 164±131             | 13±12             |
|                  | 82 (279)            | 8 (24)            |
| IgM (mg/dL)      | 871±1720            | 45±34             |
|                  | 110 (419)           | 49 (75)           |
| IgG1 (mg/dL)     | 653±335             | 315±231           |
|                  | 476 (719)           | 285 (422)         |
| IgG2 (mg/dL)     | 653±335             | 96±60             |
|                  | 476 (719)           | 90 (124)          |
| Lymphocytes count| 1,442±509           | 2,066±869         |
|                  | 1,200 (900)         | 1,850 (1,275)     |
| %B lymphocytes   | 13±16               | 9±5               |
|                  | 7 (15)              | 10 (10)           |
| B cell lymphocytes (/μL) | 129±62             | 146±66            |
|                  | 136 (106)           | 168 (127)         |
| %CD4⁺ T-lymphocytes | 37±15               | 30±7              |
|                  | 40 (29)             | 28 (8)            |
| CD4⁺ T-lymphocytes (/μL) | 649±405             | 629±264           |
|                  | 587 (623)           | 526 (537)         |
| %NK cells        | 14±6                | 16±9              |
|                  | 13 (12)             | 12 (20)           |
| NK cells (/μL)   | 295±139             | 265±206           |
|                  | 273 (294)           | 190 (431)         |

Data are presented as mean (Standard Deviation; SD); median (Interquantilic Range; IQR). Data of CLL and MALT patients are not presented (n=2).